Douglas Hay, PhD


Douglas Hay is a pharmaceutical executive with more than 20 years of experience in drug discovery with GlaxoSmithKline. Dr. Hay has particular experience in respiratory and inflammatory disease therapeutics and was most recently Vice President of the COPD Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery.

Dr. Hay received his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland.

 Glen Gaughan, PhD

David Chess, Project Operations director

Dr. David Chess has over 10 years of experience in academic research and drug discovery.  He began his industry career at Janssen Research & Development, where he was a Senior Scientist in the Cardiovascular & Metabolism therapeutic area.  As part of the heart failure team, he supported lead optimization activities for a biologic therapy and participated in NME declaration.  David then transitioned to Stealth BioTherapeutics in Newton, MA, where he assisted with pre-clinical development of mitochondrial-targeted peptides for the treatment of rare metabolic diseases.  Immediately prior to joining BioMotiv, he served as Principal Scientist at a seed-funded start-up company in Cambridge, MA, where he drove discovery efforts and managed contract research organization partnerships for cell-based therapeutic platforms.

David received his Ph.D. from Case Western Reserve University, where he examined the effects of dietary macronutrient composition on pathological left ventricular remodeling.  He completed post-doctoral fellowships at the National Heart, Lung, and Blood Institute and Boston University School of Medicine, where he investigated numerous aspects of mitochondrial biology and metabolic homeostasis.  David graduated with honors from Xavier University with a B.S. in Natural Sciences and received his M.B.A. in Entrepreneurship from Babson College.